The $195M cash infusion is a significant non-dilutive capital event for a clinical-stage biotech with a $3.7B market cap. Monitor HSR clearance timeline for closing. The proceeds extend Denali's cash runway and de-risk pipeline advancement — watch for upcoming clinical data readouts on DNL126 (Sanfilippo), DNL593 (FTD), and DNL628 (Alzheimer's) as key catalysts.
Price Chart
Executive Summary
Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The PRV was awarded following the March 2026 FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome. The $195M cash infusion is a non-dilutive capital event that strengthens Denali's balance sheet and provides funding to advance its broad clinical pipeline of TransportVehicle-enabled programs for lysosomal storage disorders and neurodegenerative diseases, including Sanfilippo syndrome, frontotemporal dementia, Pompe, and Alzheimer's. The transaction is subject to customary HSR closing conditions.
Key Financial Metrics
Key Facts
- Denali entered an asset purchase agreement to sell its Rare Pediatric Disease PRV for $195 million in cash on June 12, 2026
- PRV was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
- Proceeds will fund advancement of clinical pipeline including ETV, OTV, and ATV programs for multiple lysosomal storage disorders and neurodegenerative diseases
- Transaction subject to customary closing conditions including HSR antitrust waiting period expiration
- AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier via transferrin receptor-mediated transport
Financial Impact
$195 million non-dilutive cash infusion from PRV sale
Risk Factors
- PRV sale subject to HSR clearance — closing could be delayed
- Clinical-stage pipeline still unapproved; AVLAYAH is only approved product
- Historical reports on DNLI show negative T+20 drift — market may not reward this event
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000081 |
| Document: pressreleasedatedjune182026.htm | 0001714899-26-000081 |
| Document: 0001714899-26-000081-index-headers.html | 0001714899-26-000081 |
| Document: 0001714899-26-000081-index.html | 0001714899-26-000081 |
| Document: 0001714899-26-000081.txt | 0001714899-26-000081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 27d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access